Health Canada: Discontinuation of Acknowledgement Letters for Regulatory Activities

Health Canada: Discontinuation of Acknowledgement Letters for Regulatory Activities

March 05, 2019

On 30th Jan 2019, Health Canada issued a notice that effective from 01st April 2019, it will discontinue issuing acknowledgment letters for regulatory activities submitted by the Sponsors. These regulatory activities include the following, but not limited to:

  • Development Safety Update Report (DSUR)
  • New Drug Submission (NDS)
  • Periodic Benefit Risk Evaluation Report – Conditional (PBRER-C)
  • Periodic Safety Update Report - Conditional (PSUR-C)
  • Periodic Safety Update Report Pharmacovigilance (PSUR-PV)
  • Risk Management Plan - Pharmacovigilance (RMP-PV)
  • Undefined Pharmacovigilance (UD-PV)

It also states that the information currently found on acknowledgement letters can be obtained from the Drug Submission Tracking System – Industry Access (DSTS-IA).

This system can also be accessed by the Sponsors and Marketing Authorisation Holders to view the following details of their submissions:

  • tombstone submission information, i.e. control number (“submission number”), submission type, submission class, Lead Bureau/Office, date of filing (also known as “CR date”), dossier ID
  • drug product information, i.e. product name, manufacturer, country, active ingredient
  • status history information, i.e. submission status, status date and target date
  • review history information, i.e. review details including review type, division, status of the review (i.e. pending, active, completed) and status dates
  • document history, i.e. documents issued and received, including dates

More information on this subject and the details of setting up an account for DSTS-IA can be found in Health Canada website.


QVigilance Team
QVigilance Team

Our aim is to provide information and support through articles and updates written by our experienced team. We want to share our knowledge and create an archive of information that you will be able to engage with, share and comment on.

Leave your comments here